
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Lifecore Biomedical Inc. (LFCR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LFCR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $10
1 Year Target Price $10
2 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.42% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 303.24M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 3 | Beta 0.67 | 52 Weeks Range 3.68 - 8.63 | Updated Date 06/29/2025 |
52 Weeks Range 3.68 - 8.63 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -34.27% | Operating Margin (TTM) -6.52% |
Management Effectiveness
Return on Assets (TTM) -3.11% | Return on Equity (TTM) -83.58% |
Valuation
Trailing PE - | Forward PE 8.67 | Enterprise Value 428346587 | Price to Sales(TTM) 2.33 |
Enterprise Value 428346587 | Price to Sales(TTM) 2.33 | ||
Enterprise Value to Revenue 3.29 | Enterprise Value to EBITDA 8.11 | Shares Outstanding 37025300 | Shares Floating 19405716 |
Shares Outstanding 37025300 | Shares Floating 19405716 | ||
Percent Insiders 1.3 | Percent Institutions 72.41 |
Analyst Ratings
Rating 2 | Target Price 10 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lifecore Biomedical Inc.
Company Overview
History and Background
Lifecore Biomedical Inc. (LFCR) is a global biotechnology company specializing in the development, manufacture, and marketing of injectable pharmaceutical products and medical devices. It has evolved to focus on contract development and manufacturing organization (CDMO) services, alongside its own branded products.
Core Business Areas
- CDMO Services: Lifecore provides contract development and manufacturing services to pharmaceutical and medical device companies, focusing on sterile fill-finish and complex formulations.
- Hyaluronic Acid (HA) Based Products: Lifecore develops and manufactures HA-based products for ophthalmic, orthopedic, and aesthetic applications.
Leadership and Structure
The company is led by a management team with experience in the pharmaceutical and medical device industries. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Viscosupplementation: Lifecore manufactures hyaluronic acid-based products used for osteoarthritis treatment. Competitors include Sanofi (SNY), Zimmer Biomet (ZBH), and Anika Therapeutics (ANIK).
- Ophthalmic Solutions: Lifecore develops and manufactures HA for ophthalmic procedures. Competitors include Alcon (ALC), Bausch + Lomb (BLCO), and Johnson & Johnson (JNJ).
- CDMO Services: Lifecore provides CDMO services for fill-finish and difficult-to-manufacture products, competitors include Catalent (CTLT) and Lonza (LONN.SW)
Market Dynamics
Industry Overview
The biotechnology and pharmaceutical industries are characterized by rapid innovation, stringent regulatory requirements, and intense competition. The CDMO market is growing, driven by the increasing complexity of drug development and the need for specialized manufacturing capabilities.
Positioning
Lifecore is positioned as a CDMO with expertise in difficult to manufacture products and HA based products, allowing it to pursue opportunities in the pharmaceutical, medical device, and aesthetics markets.
Total Addressable Market (TAM)
The global CDMO market is expected to reach hundreds of billions of dollars. The global hyaluronic acid market is expected to reach billions of dollars. Lifecore is positioned to address part of this TAM through its CDMO and hyaluronic acid capabilities.
Upturn SWOT Analysis
Strengths
- Specialized expertise in HA technology
- Strong CDMO capabilities
- Established relationships with pharmaceutical and medical device companies
- Proprietary products with strong market positions
Weaknesses
- Dependence on key customers
- Exposure to regulatory risks
- Limited scale compared to larger CDMOs
- Debt burden
Opportunities
- Expanding CDMO services to new customers
- Developing new HA-based products
- Acquiring complementary technologies or businesses
- Capitalizing on the growing demand for biosimilars
Threats
- Increased competition from other CDMOs
- Changes in regulatory requirements
- Loss of key customers
- Economic downturn
Competitors and Market Share
Key Competitors
- CTLT
- LONN.SW
- SNY
- ZBH
- ANIK
- ALC
- JNJ
Competitive Landscape
Lifecore's competitive advantage lies in its hyaluronic acid expertise and its ability to handle complex formulations. Competitors vary by specific product and service offering. CDMO competitors tend to be larger and more diversified.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data unavailable due to going-private transaction
Future Projections: Future projections unavailable due to going-private transaction
Recent Initiatives: Focus on expansion of CDMO service and manufacturing capabilites prior to going private.
Summary
Lifecore Biomedical, prior to its acquisition, was a company specializing in CDMO services, particularly in hyaluronic acid-based products. Its strengths included specialized expertise and established customer relationships. Challenges included competition from larger CDMOs and regulatory risks. The acquisition by Montagu Private Equity changes the company outlook since Lifecore Biomedical Inc. is no longer publicly traded.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Press Releases
- Industry Reports
- Analyst Estimates
- SEC Filings
- Previous Investor Relations
Disclaimers:
The information provided is for general informational purposes only and does not constitute investment advice. Market share data is estimated and may vary. Recent acquisition changes company trajectory. Financial metrics might be outdated due to the acquisition and going-private transaction. All investment decisions should be made with the advice of a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lifecore Biomedical Inc.
Exchange NASDAQ | Headquaters Chaska, MN, United States | ||
IPO Launch date 1996-02-15 | President, CEO & Director Mr. Paul Josephs | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 524 | Website https://www.lifecore.com |
Full time employees 524 | Website https://www.lifecore.com |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.